The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Managing Waldenström’s macroglobulinemia in the frontline and relapsed setting
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current approaches for managing Waldenström’s macroglobulinemia (WM), highlighting uncertainties in treatment after frontline chemoimmunotherapy or BTK inhibitors. Dr Castillo mentions many drugs showing efficacy in the relapsed setting, including venetoclax, pirtobrutinib, and loncastuximab tesirine. He also mentions newer therapies, such as BTK degraders. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
